What is Avalo Therapeutics's R&D?

Avalo Therapeutics (AVTX) reported R&D of $14.05M in Q1 2026.

How has Avalo Therapeutics's R&D changed year-over-year?

Avalo Therapeutics's R&D increased by 54.0% year-over-year, from $9.12M to $14.05M.

What is the long-term trend for Avalo Therapeutics's R&D?

Over 4 years (2021 to 2025), Avalo Therapeutics's R&D has grown at a -4.3% compound annual growth rate (CAGR), from $59.84M to $50.09M.

Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.

Avalo Therapeutics AVTX R&D

R&D at other companies

Eli LillyLLY

$3.51B+28.4%

XencorXNCR

$64.67M+10.4%

AbCellera Biologics Inc.ABCL

$46.66M+9.8%

AnaptysBio, Inc.ANAB

$33.99M-17.5%

Absci CorporationABSI

$19.28M+17.8%

Vera TherapeuticsVERA

$86.01M+108%

Segments

By segment

See full

Reportable Segment$14.05M+54.0%

Other financials

Income statement

See full

Revenue$59.0K-69.3%

Gross profit$963.0K+8,855%

Operating income-$20.9M-42.5%

Net income-$19.6M-49.3%

EPS (diluted)-$0.98+21.6%

Balance sheet

See full

Cash & equivalents$25.3M-79.8%

Total debt$328.0K-59.1%

Total equity$68.3M-44.3%

Total assets$99.9M-27.9%

Cash flow

See full

Operating cash flow-$17.7M-87.1%

CapEx-—

Free cash flow-$15.0M-444%

Valuation

See full

Market cap$954.59M+1,800%

Enterprise value$929.6M-1,353%

P/S1,909.2×+1,868×

Profitability

See full

Gross margin182%+176pp

Operating margin-15,536.1%-17,275pp

Net margin-7,965.8%-10,750pp

FCF margin-11,123.8%-13,374pp

Returns & leverage

See full

Return on equity-88.8%—

Debt / equity0×0.0×

Current ratio7.7×-14.9×

Where this comes from

Reported directly by Avalo Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.

The official record: Avalo Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Avalo Therapeutics's r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Avalo Therapeutics's R&D?: Avalo Therapeutics (AVTX) reported R&D of $14.05M in Q1 2026.
How has Avalo Therapeutics's R&D changed year-over-year?: Avalo Therapeutics's R&D increased by 54.0% year-over-year, from $9.12M to $14.05M.
What is the long-term trend for Avalo Therapeutics's R&D?: Over 4 years (2021 to 2025), Avalo Therapeutics's R&D has grown at a -4.3% compound annual growth rate (CAGR), from $59.84M to $50.09M.
What does R&D mean?: Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.